Skip to main content

and
  1. Article

    Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

    Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a g...

    Dalong Zhu, **aoying Li, Jianhua Ma, Jiao’e Zeng, Shenglian Gan in Nature Medicine (2022)

  2. Article

    Open Access

    The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study

    Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcom...

    **aoling Cai, Dayi Hu, Changyu Pan, Guangwei Li, Juming Lu, Qiuhe Ji in Scientific Reports (2019)

  3. Article

    Open Access

    Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study

    Our study was aimed to investigate the gender disparities in lipid goal attainment among type 2 diabetes outpatients with concomitant coronary heart disease (CHD) and explore potential risk factors. We perform...

    **aomei Zhang, Linong Ji, **ngwu Ran, Benli Su, Qiuhe Ji, Dayi Hu in Scientific Reports (2017)

  4. No Access

    Article

    18. Acarbose Increases Gut Bacteria in Patients with Type 2 Diabetes (1040-P)

    To study the effects of acarbose add-on current therapy on gut bacteria in patients with type 2 diabetes. 119 patients with type 2 diabetes mellitus (DM), who did not take acarbose for at least one month, were...

    Benli Su, **g Li, Yongjuan Sunli, Haixia Liu in Nederlands Tijdschrift voor Diabetologie (2014)